(NASDAQ: CLNN) Clene's forecast annual revenue growth rate of 859.08% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Clene's revenue in 2026 is $197,000.On average, 7 Wall Street analysts forecast CLNN's revenue for 2026 to be $3,268,508, with the lowest CLNN revenue forecast at $1,322,112, and the highest CLNN revenue forecast at $5,396,375. On average, 7 Wall Street analysts forecast CLNN's revenue for 2027 to be $345,984,758, with the lowest CLNN revenue forecast at $2,518,309, and the highest CLNN revenue forecast at $841,834,572.
In 2028, CLNN is forecast to generate $2,541,821,327 in revenue, with the lowest revenue forecast at $287,087,174 and the highest revenue forecast at $3,575,098,742.